BioLine RX Ltd (BLRX) - Total Assets
Based on the latest financial reports, BioLine RX Ltd (BLRX) holds total assets worth ILA39.80 Million ILA (≈ $106.71K USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can BioLine RX Ltd service its debt to assess how comfortably operating cash covers total debt obligations.
BioLine RX Ltd - Total Assets Trend (2005–2024)
This chart illustrates how BioLine RX Ltd's total assets have evolved over time, based on quarterly financial data. See BioLine RX Ltd (BLRX) shareholders funds for net asset value and shareholders' equity analysis.
BioLine RX Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
BioLine RX Ltd's total assets of ILA39.80 Million consist of 69.7% current assets and 30.3% non-current assets.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 26.8% |
| Accounts Receivable | ILA3.86 Million | 9.9% |
| Inventory | ILA3.15 Million | 8.1% |
| Property, Plant & Equipment | ILA0.00 | 0.0% |
| Intangible Assets | ILA10.45 Million | 26.9% |
| Goodwill | ILA0.00 | 0.0% |
Asset Composition Trend (2005–2024)
This chart illustrates how BioLine RX Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BioLine RX Ltd market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioLine RX Ltd's current assets represent 69.7% of total assets in 2024, an increase from 0.0% in 2005.
- Cash Position: Cash and equivalents constituted 26.8% of total assets in 2024, down from 30.4% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 26.0% of total assets, an increase from 0.0% in 2005.
- Asset Diversification: The largest asset category is intangible assets at 26.9% of total assets.
BioLine RX Ltd Competitors by Total Assets
Key competitors of BioLine RX Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $2.25 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
SL Science Holding Limited Ordinary Shares
NASDAQ:SLBT
|
USA | $2.82 Million |
|
REMEGEN CO. LTD YC 1
F:REG
|
Germany | €7.25 Billion |
BioLine RX Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.09 | 1.52 | 2.15 |
| Quick Ratio | 1.93 | 1.37 | 2.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA14.86 Million | ILA12.89 Million | ILA12.24 Million |
BioLine RX Ltd - Advanced Valuation Insights
This section examines the relationship between BioLine RX Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.65 |
| Latest Market Cap to Assets Ratio | 0.29 |
| Asset Growth Rate (YoY) | -39.1% |
| Total Assets | ILA38.91 Million |
| Market Capitalization | $11.20 Million USD |
Valuation Analysis
Below Book Valuation: The market values BioLine RX Ltd's assets below their book value (0.29x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: BioLine RX Ltd's assets decreased by 39.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for BioLine RX Ltd (2005–2024)
The table below shows the annual total assets of BioLine RX Ltd from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ILA38.91 Million ≈ $104.31K |
-39.14% |
| 2023-12-31 | ILA63.92 Million ≈ $171.38K |
-16.31% |
| 2022-12-31 | ILA76.38 Million ≈ $204.78K |
-6.15% |
| 2021-12-31 | ILA81.39 Million ≈ $218.21K |
+72.11% |
| 2020-12-31 | ILA47.29 Million ≈ $126.78K |
-11.72% |
| 2019-12-31 | ILA53.57 Million ≈ $143.61K |
-4.74% |
| 2018-12-31 | ILA56.23 Million ≈ $150.76K |
-7.76% |
| 2017-12-31 | ILA60.97 Million ≈ $163.45K |
+56.57% |
| 2016-12-31 | ILA38.94 Million ≈ $104.39K |
-24.10% |
| 2015-12-31 | ILA51.30 Million ≈ $137.54K |
+41.85% |
| 2014-12-31 | ILA36.17 Million ≈ $96.96K |
+81.30% |
| 2013-12-31 | ILA19.95 Million ≈ $53.48K |
-17.93% |
| 2012-12-31 | ILA24.31 Million ≈ $65.17K |
-17.15% |
| 2011-12-31 | ILA29.34 Million ≈ $78.65K |
-81.02% |
| 2010-12-31 | ILA154.61 Million ≈ $414.51K |
-2.86% |
| 2009-12-31 | ILA159.17 Million ≈ $426.72K |
+37.54% |
| 2008-12-31 | ILA115.73 Million ≈ $310.26K |
-44.33% |
| 2007-12-31 | ILA207.88 Million ≈ $557.33K |
+933.06% |
| 2006-12-31 | ILA20.12 Million ≈ $53.95K |
-2.27% |
| 2005-12-31 | ILA20.59 Million ≈ $55.20K |
-- |
About BioLine RX Ltd
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the t… Read more